Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06764862
PHASE2

Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis

Sponsor: Haisco Pharmaceutical Group Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Official title: A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Idiopathic Pulmonary Fibrosis

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-01-27

Completion Date

2026-07-15

Last Updated

2025-01-13

Healthy Volunteers

No

Interventions

DRUG

HSK44459 dose 1

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

DRUG

HSK44459 dose 2

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

DRUG

Placebo

Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.